A recent study has shown that targeting p53 loss in adult mice using NG2-driven Cre recombination leads to the formation of bone and soft tissue sarcomas, which supports the mesenchymal origin of these tumours (Sato et al., 2016). The gene discussed is TP53; the disease is neoplasm.